Needham analyst Michael Matson has maintained their neutral stance on TFX stock, giving a Hold rating today.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Michael Matson’s rating is based on a combination of factors, including Teleflex’s recent financial performance and future outlook. The company reported better-than-expected revenue and earnings per share for the first quarter of 2025, and management has adjusted their revenue guidance upwards due to a reduced currency headwind. However, they have lowered their earnings guidance to account for the anticipated impact of tariffs, which is expected to be significant.
Despite these challenges, Matson acknowledges the potential for long-term value creation through Teleflex’s strategic separation. His analysis suggests that the company’s shares are currently undervalued. However, he also notes that there is limited visibility into the financials following recent acquisitions and spin-offs, which could restrict short-term share price growth. Therefore, he has opted for a Hold rating, reflecting a cautious stance given the mixed outlook.
According to TipRanks, Matson is an analyst with an average return of -9.5% and a 33.94% success rate. Matson covers the Healthcare sector, focusing on stocks such as Atricure, Boston Scientific, and TransMedics Group.
In another report released today, Jefferies also reiterated a Hold rating on the stock with a $145.00 price target.